TOP TIERMARKET NEWSWIRE

News & sentiment

REGENXBIO INC (RGNX) — News & AI sentiment

REGENXBIO INC (RGNX) news roundup. 14 stories aggregated over the last 30 days. Average 30-day sentiment is 37.5/100. Recent insider activity (SEC Form 4, 90-day window): 0 purchases totalling $0 and 3 sales totalling $887K — net selling of $887K. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

0

30d stories

14

avg sentiment 37.5/100

Insider net (90d)

$887K

0 buys · 3 sells

Congress (90d)

0

0 buys · 0 sells

Latest stories on RGNX

Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm

PR Newswire34 · bearishgeneral

Jul 21

RegenXBio Raises Capital Through Public Equity Offering

TipRanks28 · bearishgeneral

Jul 20

REGENXBIO Inc. (RGNX) files 8-K

SEC 8-K50 · neutralgeneral

Jul 20

REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting

Barchart73 · bullishproduct/pr

Jul 18

REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting | RGNX Stock News

StockTitan67 · bullishproduct/pr

Jul 18

REGENXBIO Announces $100 Million Common Stock Offering—What Does This Mean for Investors? July 17, 2026

MarketChameleon24 · bearishgeneral

Jul 17

REGENXBIO Targets $100 Million Capital Raise Through Public Offering of Common Stock and Pre-Funded Warrants July 17, 2026

MarketChameleon28 · bearishgeneral

Jul 17

REGENXBIO stock dips on $100M equity offering

Seeking Alpha24 · bearishgeneral

Jul 17

REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants

PR Newswire24 · bearishgeneral

Jul 17

RGNX Stock Slumps 15% After-Hours — What’s Driving The Selloff?

Stocktwits News24 · bearishgeneral

Jul 16

REGENXBIO files prospectus for up to $100M common stock offering

Seeking Alpha24 · bearishgeneral

Jul 16

REGENXBIO Announces Proposed Public Offering of Common Stock

PR Newswire24 · bearishgeneral

Jul 16

REGENXBIO Announces Proposed Public Offering of Common Stock | RGNX Stock News

StockTitan28 · bearishgeneral

Jul 16

Regenxbio Shares Rise on $100 Million Milestone Payment After First Patient Dosed in Eye-Disease Trial

Morningstar73 · bullishgeneral

Jul 1

Regenxbio Advances Diabetic Retinopathy Gene Therapy Trial

TipRanks63 · neutralproduct/pr

Jun 29

REGENXBIO Inc. (RGNX) files 8-K

SEC 8-K50 · neutralgeneral

Jun 29

REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone

PR Newswire63 · neutralproduct/pr

Jun 29

Regenxbio: 'Strong Buy' On FDA Course Reversal For NAVSUNLI And Potential AA DMD Filing

Seeking Alpha73 · bullishanalyst

Jun 28

REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026 | RGNX Stock News

StockTitan73 · bullishproduct/pr

Jun 24

AbbVie's Deal with Apogee; Regenxbio Moves on Gene Therapy Drug | Stock Movers

Bloomberg73 · bullishm&a

Jun 22

RGNX Retail Investors See Hope As FDA Reopens Door For Regenxbio’s Hunter Syndrome Therapy

Stocktwits News58 · neutralgeneral

Jun 22

Regenxbio Shares Up on WSJ Report of FDA U-Turn on Company's Gene Therapy

Morningstar67 · bullishgeneral

Jun 22

FDA Fast-Tracks REGENXBIO Gene Therapy NAVSUNLI—First Accelerated Approval Pathway for MPS II in Sight

MarketChameleon76 · bullishproduct/pr

Jun 22

Regenxbio: Duchenne Data Keeps Me Bullish, There's Less Room For Setbacks Now

Seeking Alpha66 · bullishgeneral

Jun 22

REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II | RGNX Stock News

StockTitan63 · neutralgeneral

Jun 22

Open RGNX in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →